Clinical Trials Browser

Phase 1/2 × Alpelisib × Clear all

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

HER2-positive Metastatic Breast Cancer

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT04997902 2025-12-23

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 1/2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT04753203 2023-10-31

ALCAP

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT02379247 2022-06-07

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Phase 1/2 Completed

43 enrolled 18 charts

Breast Neoplasms

NCT04526470 2021-08-24

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

Phase 1/2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT01602315 2020-12-29

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

179 enrolled 38 charts

Squamous Cell Carcinoma of Head and Neck, Hereditary Sensory and Autonomic Neuropathies

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Phase 1/2 Terminated

47 enrolled 23 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms